Current topics in CAR T-cell therapy

The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 1

Oct 2023
Duration 25 mins 19 secs

These are recordings of Kite’s symposia at CANO 2023 entitled “The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma”. In this 3-part series, speakers from CAR T treatment centres across Canada will discuss the role of nurses in a patient’s path to CAR T therapy and post-treatment care with R/R LBCL. They will also share best practices on patient management and co-ordination of patient care between nurses at referral and CAR T centres.  In Part 1, Laurie Ann Holmes provides an overview of the CAR T journey, while Giselle Wilson discusses nursing care prior to cell collection. In Part 2, Cheryl Page reviews nursing considerations around CAR T administration. Finally in Part 3, Rachel Nielsen wraps up the session with the topic of nursing care post-CAR T infusion, including long term follow-up and shared care. A brief panel discussion concludes the session.

Watch
The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 1

Evolving Survival Outcomes with CAR T in 2L DLBCL

Jun 2023
Duration 10 mins 27 secs

As part of Kite’s symposia at ICML 2023 entitled “CAR T in 2L DLBCL: A case study”, Dr. Westin presents three of his patients with DLBCL who require treatment in the 2L setting, and reviews clinical evidence to guide potential treatment options.

Watch
Evolving Survival Outcomes with CAR T in 2L DLBCL

Understanding the Role of CAR T in R/R Adult ALL and Exploring CAR T Treatment Approaches in R/R Adult ALL

Jun 2023
Duration 27 mins 21 secs

As part of Kite’s symposia at EHA 2023 entitled “Managing R/R Adult ALL in the CAR T Era”, Dr. Shah and Dr. Rabian discuss CAR T treatment approaches in R/R adult ALL, including clinical trial and real-world data updates, as well as present real patient cases.

Watch
Understanding the Role of CAR T in R/R Adult ALL and Exploring CAR T Treatment Approaches in R/R Adult ALL

Expert Discussion on CAR T Therapy for Relapsed and Refractory Mantle Cell Lymphoma

Jan 2023
Duration 32 mins 14 secs

In this video, Dr. Herbaux highlights emerging data and discusses his experience on the management of patients with R/R MCL. Specifically, he reviews clinical data and real-world evidence for CAR T therapy in R/R MCL, shares best-practices on patient identification, disease monitoring and management prior to CAR T infusion as well as long-term patient care post-infusion.

Watch
Expert Discussion on CAR T Therapy for Relapsed and Refractory Mantle Cell Lymphoma

CAR T Therapy in Aggressive Lymphoma: New Care Standards and Redefining Survival for Canadian Patients - Part 1

Jun 2023
Duration 22 mins 33 secs

These are recordings of Kite’s symposia at CTTC 2023 entitled “CAR T Cell Therapy in Aggressive Lymphoma: New Care Standards and Redefining Survival for Canadian Patients”. In Part 1, Dr. Sita Bhella discusses the Canadian experience with CAR T cell therapy for R/R LBCL from referral to follow up, including best practices on integrating CAR T therapy into clinical practice. In Part 2, Dr. Caron Jacobson shares key learnings from the US experience incorporating CAR T therapy as second-line treatment. 

Watch
CAR T Therapy in Aggressive Lymphoma: New Care Standards and Redefining Survival for Canadian Patients - Part 1

Webinars & Tutorials

Visit page
Expert Discussion on CAR T Therapy for Relapsed and Refractory Mantle Cell Lymphoma

Expert Discussion on CAR T Therapy for Relapsed and Refractory Mantle Cell Lymphoma

Jan 2023
Duration 32 mins 14 secs

In this video, Dr. Herbaux highlights emerging data and discusses his experience on the management of patients with R/R MCL. Specifically, he reviews clinical data and real-world evidence for CAR T therapy in R/R MCL, shares best-practices on patient identification, disease monitoring and management prior to CAR T infusion as well as long-term patient care post-infusion.

View
Expert Discussions on Practical Considerations for Using CAR T-Cell Therapy

Expert Discussions on Practical Considerations for Using CAR T-Cell Therapy

May 2022
Duration 19 mins 59 secs

During this discussion, CAR T experts and referring physicians review current guidelines and recommendations for the treatment of R/R DLBCL, as well as key patient selection criteria for CAR T. Speakers discuss clinical considerations for patients at all stages of the CAR T journey from pre-infusion to follow-up.

View

Congress Symposia

Visit page
The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 1

The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 1

Oct 2023
Duration 25 mins 19 secs

These are recordings of Kite’s symposia at CANO 2023 entitled “The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma”. In this 3-part series, speakers from CAR T treatment centres across Canada will discuss the role of nurses in a patient’s path to CAR T therapy and post-treatment care with R/R LBCL. They will also share best practices on patient management and co-ordination of patient care between nurses at referral and CAR T centres.  In Part 1, Laurie Ann Holmes provides an overview of the CAR T journey, while Giselle Wilson discusses nursing care prior to cell collection. In Part 2, Cheryl Page reviews nursing considerations around CAR T administration. Finally in Part 3, Rachel Nielsen wraps up the session with the topic of nursing care post-CAR T infusion, including long term follow-up and shared care. A brief panel discussion concludes the session.

View
CAR T Therapy in Aggressive Lymphoma: New Care Standards and Redefining Survival for Canadian Patients - Part 1

CAR T Therapy in Aggressive Lymphoma: New Care Standards and Redefining Survival for Canadian Patients - Part 1

Jun 2023
Duration 22 mins 33 secs

These are recordings of Kite’s symposia at CTTC 2023 entitled “CAR T Cell Therapy in Aggressive Lymphoma: New Care Standards and Redefining Survival for Canadian Patients”. In Part 1, Dr. Sita Bhella discusses the Canadian experience with CAR T cell therapy for R/R LBCL from referral to follow up, including best practices on integrating CAR T therapy into clinical practice. In Part 2, Dr. Caron Jacobson shares key learnings from the US experience incorporating CAR T therapy as second-line treatment. 

View
Evolving Survival Outcomes with CAR T in 2L DLBCL

Evolving Survival Outcomes with CAR T in 2L DLBCL

Jun 2023
Duration 10 mins 27 secs

As part of Kite’s symposia at ICML 2023 entitled “CAR T in 2L DLBCL: A case study”, Dr. Westin presents three of his patients with DLBCL who require treatment in the 2L setting, and reviews clinical evidence to guide potential treatment options.

View
Understanding the Role of CAR T in R/R Adult ALL and Exploring CAR T Treatment Approaches in R/R Adult ALL

Understanding the Role of CAR T in R/R Adult ALL and Exploring CAR T Treatment Approaches in R/R Adult ALL

Jun 2023
Duration 27 mins 21 secs

As part of Kite’s symposia at EHA 2023 entitled “Managing R/R Adult ALL in the CAR T Era”, Dr. Shah and Dr. Rabian discuss CAR T treatment approaches in R/R adult ALL, including clinical trial and real-world data updates, as well as present real patient cases.

View
Navigating the New Paths to Redefine Survival in MCL Treatment

Navigating the New Paths to Redefine Survival in MCL Treatment

Jun 2021
Duration 25 mins 16 secs

As part of Kite’s symposia at EHA 2021 entitled “Redefining survival in adult hematological malignancies: The role of CAR T”, Profs. Davies and Hess highlight unmet needs in R/R MCL, discuss emerging therapies including CAR T, and provide clinical guidance in navigating the patient journey.

View
Survival in R/R DLBCL with CAR T: How long can we go?

Survival in R/R DLBCL with CAR T: How long can we go?

Mar 2022
Duration 16 mins 9 secs

As part of Kite’s symposia at EBMT 2022 entitled “5 years and counting: Building survival in lymphoma with CAR T”, Dr. Westin provides clinical trial and real-world data updates on CAR T therapy for relapsed or refractory large B-cell lymphoma.

View